126 related articles for article (PubMed ID: 34969749)
21. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
22. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
[TBL] [Abstract][Full Text] [Related]
23. Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.
Cho YK; Sborov DW; Lamprecht M; Li J; Wang J; Hade EM; Gao Y; Tackett K; Williams N; Benson DM; Efebera YA; Rosko AE; Devine SM; Poi M; Hofmeister CC; Phelps MA
Clin Pharmacol Ther; 2017 Sep; 102(3):511-519. PubMed ID: 28160288
[TBL] [Abstract][Full Text] [Related]
24. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
25. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Lilleby K; Garcia P; Gooley T; McDonnnell P; Taber R; Holmberg L; Maloney DG; Press OW; Bensinger W
Bone Marrow Transplant; 2006 Jun; 37(11):1031-5. PubMed ID: 16633359
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.
Marcussen M; Bødker JS; Christensen HS; Johansen P; Nielsen S; Christiansen I; Bergmann OJ; Bøgsted M; Dybkær K; Vyberg M; Johnsen HE
PLoS One; 2017; 12(1):e0169286. PubMed ID: 28052121
[TBL] [Abstract][Full Text] [Related]
27. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Abidi MH; Agarwal R; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Ratanatharathorn V; Zonder J; Uberti J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):56-61. PubMed ID: 22892551
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.
Moeez S; Riaz S; Masood N; Kanwal N; Arif MA; Niazi R; Khalid S
Can J Diabetes; 2019 Mar; 43(2):128-135.e3. PubMed ID: 30297296
[TBL] [Abstract][Full Text] [Related]
30. Factors influencing the incidence and severity of oral mucositis in patients undergoing autologous stem cell transplantation.
Salvador PT
Can Oncol Nurs J; 2005; 15(1):29-34. PubMed ID: 15779780
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
de Paula Eduardo F; Bezinelli LM; da Graça Lopes RM; Nascimento Sobrinho JJ; Hamerschlak N; Correa L
Hematol Oncol; 2015 Sep; 33(3):152-8. PubMed ID: 24519448
[TBL] [Abstract][Full Text] [Related]
33. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
Mølle I; Peterslund NA; Thiel S; Steffensen R
Bone Marrow Transplant; 2006 Oct; 38(8):555-60. PubMed ID: 16953214
[TBL] [Abstract][Full Text] [Related]
34. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
35. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
36. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients.
Milstein DM; te Boome LC; Cheung YW; Lindeboom JA; van den Akker HP; Biemond BJ; Ince C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jan; 109(1):91-7. PubMed ID: 20123381
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the adverse effects of melphalan formulations.
Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
[TBL] [Abstract][Full Text] [Related]
38. Polymorphic Variants rs3088442 and rs2292334 in the Organic Cation Transporter 3 (OCT3) Gene and Susceptibility Against Type 2 Diabetes: Role of their Interaction.
Mahrooz A; Alizadeh A; Hashemi-Soteh MB; Ghaffari-Cherati M; Hosseyni-Talei SR
Arch Med Res; 2017 Feb; 48(2):162-168. PubMed ID: 28625319
[TBL] [Abstract][Full Text] [Related]
39. High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA
Ann Transplant; 2002; 7(2):38-43. PubMed ID: 12416471
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma.
Blanes M; González JD; Lahuerta JJ; Ribas P; Lorenzo I; Boluda B; Sanz MA; de la Rubia J
Leuk Lymphoma; 2015 Feb; 56(2):415-9. PubMed ID: 24828869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]